An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 01/25/2026 2:26 AM
Question 20250026
Inquiry Details
References:
#1: Solid Tumor Rules. 2025 Update
#2: WHO Class Digest System Tumors. 5th edition, online version
Question:
Solid Tumor Rules/Histology--Esophagus: Are SMARCA4- deficient malignant neoplasms (8020/3) valid for esophagus or other sites besides lung? See Discussion.
Discussion:
SINQ 20200057 states to use SMARCA4-deficient malignant neoplasms newly identified to use 8020/3 in this example for lung. The annotated histology list shows this histology followed by (C34._) for 2023 forward. An esophagus pathology states the following, "The histologic features and immunohistochemical profile are those of a SMARCA2/SMARCA4-deficient malignant neoplasm." Is the 8020/3 histology valid for esophagus or other sites?
Answer:
Assign 8020/3 for SMARCA4- deficient malignant neoplasms of the esophagus.
The WHO Classification of Digestive System Tumors, 5th edition, lists undifferentiated carcinoma as 8020/3. Undifferentiated carcinoma of the esophagus is characterized by the frequent loss of SMARCA4 or SMARCA2 by immunohistochemistry.
SINQ 20200057 was updated in August 2025 and assigns code 8044/3 for Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). The 2025 Solid Tumor Manual includes SMARCA4-deficient or SMARCB1-deficient tumors for thoracic and sinonasal sites (8044/3).
Assigning histology to other individual sites should be on a case-by-case basis.
